GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: compound 1 [WO2022017494]
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Socrodeucitinib is the INN for a (deuterated) Janus kinase inhibitor with anti-inflammatory potential (included in WHO INN proposed list 133, 10th July 2025). The structure is claimed as compound 1 in patent WO2022017494A1 (Hansoh Biopharmaceutical), and is proposed as a TYK2 inhibitor [1]. Hansoh have TYK2 inhibitor HS-10374 in phase 2 and 3 clinical trials for psoriatic arthritis and psoriasis, but we are unable to confirm a name-to-structure match at this time (July 2025).
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Du J, Ma L. (2022)
                                         Crystal form of pyridazine derivative free base, and preparation method therefor and use thereof. Patent number: WO2022017494A1. Assignee: Shanghai Hansoh Biopharmaceutical Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. Priority date: 23/07/2021. Publication date: 27/01/2022.  |